Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2016 1
2018 1
2019 2
2020 4
2021 3
2022 5
2023 10
2024 11
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean oche jb cancer (1 results)?
Enhanced recovery after surgery protocol does not reduce the length of postoperative hospitalization after robot-assisted radical prostatectomy. Outcomes from the first randomized controlled trial: the (PROSTA-RAAC) study.
Pierquet G, Prévost E, Lopez L, Gaston R, Rouffilange J, Riviere J, Roche JB, Vuong N, Genty A, Hoepffner JL, Asimakopoulos AD, Piechaud PT. Pierquet G, et al. Among authors: roche jb. World J Urol. 2025 Nov 15;43(1):699. doi: 10.1007/s00345-025-06078-2. World J Urol. 2025. PMID: 41240114 Clinical Trial.
METHODS: 129 consecutive patients affected by prostate cancer were randomly assigned to standard-of-care (SoC, 61 patients) or ERAS perioperative protocol (68 patients) during hospitalization for RARP. ...
METHODS: 129 consecutive patients affected by prostate cancer were randomly assigned to standard-of-care (SoC, 61 patients) or ERAS p …
Outcomes of lateral approach in robot-assisted radical prostatectomy: insights from a single-surgeon experience.
Giulioni C, Castellani D, Vuong NS, Riviere J, Piechaud-Kressmann J, Lopez LH, Piechaud T, Roche JB, Rouffilange J, Hoepffner JL, Galosi AB, Gaston RP, Pierquet G. Giulioni C, et al. Among authors: roche jb. J Robot Surg. 2024 Jan 13;18(1):24. doi: 10.1007/s11701-023-01772-y. J Robot Surg. 2024. PMID: 38217830 Free PMC article.
We conducted a retrospective analysis of 70 prostate cancer patients who underwent LRRP between October 2019 and September 2021, analyzing the perioperative and functional outcomes. ...Our analysis shows that LRRP is a safe and effective procedure for prostate cancer …
We conducted a retrospective analysis of 70 prostate cancer patients who underwent LRRP between October 2019 and September 2021, anal …
Transrectal versus transperineal prostate fusion biopsy: a pair-matched analysis to evaluate accuracy and complications.
Oderda M, Diamand R, Abou Zahr R, Anract J, Assenmacher G, Barry Delongchamps N, Bui AP, Benamran D, Calleris G, Dariane C, Ferriero M, Fiard G, Taha F, Fourcade A, Fournier G, Guenzel K, Halinski A, Marra G, Ploussard G, Rysankova K, Roche JB, Simone G, Windisch O, Gontero P. Oderda M, et al. Among authors: roche jb. World J Urol. 2024 Sep 25;42(1):535. doi: 10.1007/s00345-024-05245-1. World J Urol. 2024. PMID: 39320521 Free PMC article.
Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracy.
Diamand R, Peltier A, Roche JB, Lievore E, Lacetera V, Chiacchio G, Beatrici V, Mastroianni R, Simone G, Windisch O, Benamran D, Fourcade A, Nguyen TA, Fournier G, Fiard G, Ploussard G, Roumeguère T, Albisinni S. Diamand R, et al. Among authors: roche jb. World J Urol. 2023 Jan;41(1):77-84. doi: 10.1007/s00345-022-04244-4. Epub 2022 Dec 12. World J Urol. 2023. PMID: 36509932
External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.
Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A. Diamand R, et al. Among authors: roche jb. World J Urol. 2024 Jun 12;42(1):372. doi: 10.1007/s00345-024-05068-0. World J Urol. 2024. PMID: 38866949
The aim is to externally validate and compare risk prediction models for the diagnosis of clinically significant prostate cancer (csPCa). METHODS: A cohort of 4606 patients across fifteen European tertiary referral centers were identified from a prospective maintained data …
The aim is to externally validate and compare risk prediction models for the diagnosis of clinically significant prostate cancer (csP …
Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
Fitoussi O, Roche JB, Riviere J, Wallerand H, Poulain JE, Gordien P, Galland S, Henriques B, Dupin C, Vincent M, Kuratle T, Saffarini M, Ramos-Pascual S. Fitoussi O, et al. Among authors: roche jb. Urol Int. 2023;107(3):239-245. doi: 10.1159/000528524. Epub 2023 Jan 19. Urol Int. 2023. PMID: 36657430
INTRODUCTION: The aim of the study was to confirm the diagnostic accuracy of a second FDG-PET/CT following neoadjuvant or induction chemotherapy (NAIC) prior to radical cystectomy for patients with localized muscle-invasive bladder cancer (MIBC). METHODS: Retrospective rev …
INTRODUCTION: The aim of the study was to confirm the diagnostic accuracy of a second FDG-PET/CT following neoadjuvant or induction chemothe …
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach.
Baboudjian M, Breda A, Roumeguère T, Uleri A, Roche JB, Touzani A, Lacetera V, Beauval JB, Diamand R, Simone G, Windisch O, Benamran D, Fourcade A, Fiard G, Durand-Labrunie C, Roumiguié M, Sanguedolce F, Oderda M, Barret E, Fromont G, Dariane C, Charvet AL, Gondran-Tellier B, Bastide C, Lechevallier E, Palou J, Ruffion A, Van Der Bergh RCN, Peltier A, Ploussard G. Baboudjian M, et al. Among authors: roche jb. World J Urol. 2023 May;41(5):1301-1308. doi: 10.1007/s00345-023-04353-8. Epub 2023 Mar 15. World J Urol. 2023. PMID: 36920491
PURPOSE: To develop new selection criteria for active surveillance (AS) in intermediate-risk (IR) prostate cancer (PCa) patients. METHODS: Retrospective study including patients from 14 referral centers who underwent pre-biopsy mpMRI, image-guided biopsies and radical pros …
PURPOSE: To develop new selection criteria for active surveillance (AS) in intermediate-risk (IR) prostate cancer (PCa) patients. MET …
Predicting contralateral extraprostatic extension in unilateral high-risk prostate cancer: a multicentric external validation study.
Diamand R, Roche JB, Lacetera V, Simone G, Windisch O, Benamran D, Fourcade A, Fournier G, Fiard G, Ploussard G, Roumeguère T, Peltier A, Albisinni S. Diamand R, et al. Among authors: roche jb. World J Urol. 2024 Apr 22;42(1):247. doi: 10.1007/s00345-024-04966-7. World J Urol. 2024. PMID: 38647728
Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The aim of the study is to externally validate this model in a multicentric European cohort of patients. ...
Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The …
The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy.
Bourgeno HA, Jabbour T, Baudewyns A, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Vlahopoulos L, Guenzel K, Roumeguère T, Peltier A, Diamand R. Bourgeno HA, et al. Among authors: roche jb. Eur Urol Oncol. 2024 Dec;7(6):1320-1326. doi: 10.1016/j.euo.2024.01.007. Epub 2024 Jan 24. Eur Urol Oncol. 2024. PMID: 38272745
PATIENT SUMMARY: In the present study, we collected a set of patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies for the detection of prostate cancer. We found that biopsies taken at the opposite side of the MRI suspicious lesion have a …
PATIENT SUMMARY: In the present study, we collected a set of patients who underwent magnetic resonance imaging (MRI)-targeted and systematic …
Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection.
Diamand R, Guenzel K, Mjaess G, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Benijts J, Assenmacher G, Roumeguère T, Peltier A. Diamand R, et al. Among authors: roche jb. Eur Urol Focus. 2024 Sep;10(5):805-811. doi: 10.1016/j.euf.2024.03.003. Epub 2024 Mar 19. Eur Urol Focus. 2024. PMID: 38508895
The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to compare the csPCa detection rate of TRBx and TPBx. ...Our results suggest that the perineal approach is associated with better detection of …
The impact of this change on detection of clinically significant prostate cancer (csPCa) remains a subject of debate. Our aim was to …
34 results